Christine M. McMahon

Author

Also Known As

Abby Grier, C McMahon, C.M. McMahon, Christine M. McMahon, Christine M. Mcmahon, Christine McMahon, Christine Mcmahon, McMahon, Christine

231

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Denver University of Pennsylvania Albert Einstein College of Medicine Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center

About

Christine M. McMahon is an author at University of Colorado Denver specializing in medicine, hematology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	18	1.6K
2	Health Sciences	3	3	248
3	Natural Sciences	2	2	225
4	Public Health	1	1	89
5	Allergy	1	1	15

Christine M. McMahon

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
( <i>R</i> )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible Julie-Aurore Losman, Ryan Looper, Peppi Koivunen, Science	2013	700
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia Christine M. McMahon, Timothy T. Ferng, Jonathan Canaani, Cancer Discovery	2019	412
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations Britta Will, Li Zhou, Thomas O. Vogler, Blood	2012	238
P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor Christine M. McMahon, Tuangporn Suthiphongchai, James DiRenzo, Proceedings of the National Academy of Sciences Cyclin D1Estrogen ReceptorPharmacotherapyOvarian CancerSignaling Pathway	1999	182
Optical Redox Ratio Differentiates Breast Cancer Cell Lines Based on Estrogen Receptor Status Julie H. Ostrander, Christine M. McMahon, Siya Lem, Cancer Research Optical Redox RatioBreast OncologyOncologic ImagingAutofluorescence SpectroscopyRedox Biology	2010	182
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia Evan Cherry, Diana Abbott, Maria L. Amaya, Blood Advances Hematological MalignancyMedicineAcute Myeloid LeukemiaMixed-phenotype Acute LeukemiaHematology	2021	160
Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) Ghayas C. Issa, Ibrahim Aldoss, Michael J. Thirman, Journal of Clinical Oncology	2024	136
Reduced SMAD7 Leads to Overactivation of TGF-β Signaling in MDS that Can Be Reversed by a Specific Inhibitor of TGF-β Receptor I Kinase Li Zhou, Christine M. McMahon, Tushar D. Bhagat, Cancer Research Smad7 LeadsTgf-β ReceptorImmunologyImmune RegulationPathology	2010	132
Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia Britta Will, Thomas O. Vogler, Swathi Narayanagari, Nature Medicine Hematological MalignancyMixed-phenotype Acute LeukemiaAcute Myeloid LeukemiaHematologyMyeloid Neoplasia	2015	126
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022 Peter L. Greenberg, Richard M. Stone, Aref Al‐Kali, Journal of the National Comprehensive Cancer Network Hematological MalignancyFamily MedicineNccn Guidelines® InsightsOncologyBone Marrow Failure	2022	121

Page 1